Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerucin in healthy adults
NCT02486770Phase 1Completed
- Sponsor
- Aridis Pharmaceuticals, Inc.
- Start
- Apr 2015
- Primary completion
- Sep 2015
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of aerucin in Pseudomonas aeruginosa infection (3 arms), sponsored by Aridis Pharmaceuticals, Inc. Primary endpoints: Adverse Events at 84 days, Serious Adverse Events at 84 days and 1 more. Started Apr 2015; status: completed.
02
Drugs
aerucin
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02486770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486770.